Citations (5)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
William C. S. Cho, Ka-Po Tse, Roger K. C. Ngan, Wah Cheuk, Victor W. S. Ma, Yi-Ting Yang, Timothy T. C. Yip, Kien Thiam Tan & Shu-Jen Chen. (2020) Genomic characterization reveals potential biomarkers in nasopharyngeal carcinoma patients with relapse. Expert Review of Molecular Diagnostics 20:11, pages 1149-1159.
Read now
Read now
Zeynep Aygün, Şebnem Batur, Şenol Emre, Tiraje Celkan, Oktay Özman & Nil Comunoglu. (2019) Frequency of ALK and GD2 Expression in Neuroblastoma. Fetal and Pediatric Pathology 38:4, pages 326-334.
Read now
Read now
Articles from other publishers (3)
Carlos Murga-Zamalloa & Kedar Inamdar. (2022) Classification and challenges in the histopathological diagnosis of peripheral T-cell lymphomas, emphasis on the WHO-HAEM5 updates. Frontiers in Oncology 12.
Crossref
Crossref
Yasemin Benderli Cihan. (2018) Role of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib in the Management of Neuroblastoma. Serbian Journal of Experimental and Clinical Research 0:0.
Crossref
Crossref
Frank M. Balis, Patrick A. Thompson, Yael P. Mosse, Susan M. Blaney, Charles G. Minard, Brenda J. Weigel & Elizabeth Fox. (2016) First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children’s Oncology Group Phase 1/Pilot Consortium. Cancer Chemotherapy and Pharmacology 79:1, pages 181-187.
Crossref
Crossref